Myocardial cGMP-PKG1alpha dysregulation contributes to VT pathogenesis in type II diabetes and metabolic syndrome.
Xuehong Cao, Yali Zhang, Audrey Tripp, Rachael Steinhauer, Peiwen Liu, Mark J. Aronovitz, Gregory Martin, Bo Wang, Abdullah Alissa, Mossab Aljuaid, Justin Ho, Tina Phan, Christopher A. Madias, Robert M. Blanton, Jonas Galper
This study identifies cGMP reduction as a driver of VT in DMII and metabolic syndrome, showing that pharmacological modulation of cGMP-PKG1alpha pathways can reduce VT inducibility.
bioRxiv · Feb 12, 2025 · PreprintMolecular Biology